Nov 03, 2016 12:01 pm UTC| Business
Top-line results from both the ongoing Phase III clinical study for acute gastroenteritis and gastritis and the ongoing Phase II clinical study for diarrhea-predominant irritable bowel syndrome (IBS-D) are expected in...
Fibrocell Reports Third Quarter 2016 Financial Results and Recent Operational Highlights
Nov 03, 2016 12:01 pm UTC| Business
EXTON, Pa., Nov. 03, 2016 -- Fibrocell Science, Inc. (NASDAQ:FCSC) today reported financial results for the third quarter ended September 30, 2016 and recent operational highlights. Fibrocell will host a conference call...
Nov 03, 2016 12:01 pm UTC| Business
NEW YORK and LONDON, Nov. 03, 2016 -- Akari Therapeutics (NASDAQ:AKTX), an emerging growth, clinical-stage biopharmaceutical company, announced today that an abstract has been accepted at the 58th Annual Meeting of the...
Nov 03, 2016 12:01 pm UTC| Business
DENVER, Nov. 03, 2016 -- Bang Holdings Corp. (OTCQB:BXNG), through its wholly owned subsidiary Bang Digital Media, today announced its “Donald Bot” is delivering impressive real-world productivity test-market results,...
Nov 03, 2016 12:01 pm UTC| Business
HORSHAM, Pa., Nov. 03, 2016 -- Toll Brothers, Inc. (NYSE:TOL) (www.TollBrothers.com), the nation’s leading builder of luxury homes, through its Toll Brothers Apartment Living subsidiary, along with its joint venture...
Semtech Introduces New ESD Protection Platform Optimized for Ultra-High Speed Interfaces
Nov 03, 2016 12:01 pm UTC| Business
CAMARILLO, Calif., Nov. 03, 2016 -- Semtech Corporation (Nasdaq:SMTC), a leading supplier of analog and mixed-signal semiconductors, today unveiled the FemtoClamp™ product platform with the release of the RClamp® 0561Z....
Spark Therapeutics Reports Third Quarter 2016 Financial Results and Recent Business Highlights
Nov 03, 2016 12:01 pm UTC| Business
Completion of Biologics Licensing Application (BLA) submission for investigational candidate voretigene neparvovec on track for early 2017 Company makes progress across multiple programs, including its hemophilia...